An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Latest Information Update: 24 Dec 2024
Price :
$35 *
At a glance
- Drugs Lumateperone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 19 Dec 2024 Status changed from recruiting to completed.
- 07 Jan 2024 This trial has been Discontinued at Finland, According to European Clinical Trials Database record.
- 01 Oct 2021 New trial record